Tempus AI, Inc. (TEM) stock: key figures, P/E, revenue and dividend
Information Technology · United States · ISIN US88023B1035
Tempus AI, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 1.27 bn USD |
| Operating income | -252.87 m USD |
| EBIT | -239.07 m USD |
| Net income | -245.03 m USD |
| Diluted EPS – continuing operations | -1.41 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Tempus AI, Inc.
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
More stocks
- HAIN CELESTIAL GROUP INC (HAIN)
- Next Technology Holding Inc. (NXTT)
- BioCardia, Inc. (BCDA)
- Ascent Solar Technologies, Inc. (ASTI)
- BARNWELL INDUSTRIES INC (BRN)
- SPAR Group, Inc. (SGRP)
- M2i Global, Inc. (MTWO)
- FEMASYS INC (FEMY)
- Nomadar Corp. (NOMA)
- URBAN ONE, INC. (UONE)
- Fabric.AI, Inc. (FABC)
- AIR INDUSTRIES GROUP (AIRI)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.